Biotechnology company focused on identifying and developing transformative therapies for rare diseases.
Rallybio Corporation is an innovative clinical-stage biotechnology firm dedicated to the discovery, development, manufacturing, and delivery of therapies designed to significantly improve the lives of patients grappling with severe and rare diseases. Founded in 2018 and based in New Haven, Connecticut, the company is committed to advancing a robust pipeline of therapeutic candidates.
At the forefront of Rallybio's portfolio is RLYB212, a monoclonal anti-HPA-1a antibody currently undergoing Phase I clinical trials. This candidate is targeted at preventing fetal and neonatal alloimmune thrombocytopenia (FNAIT), a condition that poses serious risks during pregnancy and childbirth. Additionally, the company is developing RLYB211, a polyclonal anti-HPA-1a antibody in Phase 1/2 trials, also aimed at addressing FNAIT.
Further expanding its therapeutic offerings, Rallybio is progressing RLYB114, a pegylated complement factor 5 (C5)-targeted Affibody molecule, through preclinical development. This potential treatment targets complement-mediated ophthalmic diseases. Additionally, RLYB116, a subcutaneously administered C5 inhibitor, is under development for patients grappling with paroxysmal nocturnal hemoglobinuria and generalized myasthenia gravis.
Rallybio is actively fostering collaboration and innovation in rare disease therapeutics. The company has formed a strategic partnership with Exscientia to advance small molecule therapeutics, underscoring its commitment to leveraging cutting-edge technology and expertise to tackle unmet medical needs. With a focus on scientific excellence and patient-centric innovation, Rallybio Corporation continues to push the boundaries of biotechnology, aiming to bring transformative therapies to patients worldwide.